Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Spire

Nov 08, 2018 12:45 PM - Nov 09, 2018 4:00 PM

750 First Street NE, Washington, DC 20002

Master Protocol Workshop

Session 3: An In-Depth Look at EPAD

Session Chair(s)

Scott  Berry, PhD

Scott Berry, PhD

President and Senior Statistical Scientist

Berry Consultants LLC, United States

Daniel  Millar, MBA

Daniel Millar, MBA

Senior Director, Strategic Business Transformation

Johnson & Johnson, United States

The I-Spy2 trial helped create the platform trial. It has had an amazing record of success and innovation. EPAD is an IMI sponsored phase II platform trial in Alzheimer’s disease and has the potential to change the course of Alzheimer’s with the innovative platform trial. Each of these trials will be presented and discussed in-depth both from a design, operation, and strategy perspective.

Speaker(s)

Lisa  Ford

Lisa Ford

Janssen Pharmaceuticals, United States

Senior Director, Neuroscience Research and Development

Mark  Fitzgerald, PhD

An In-Depth Look at EPAD

Mark Fitzgerald, PhD

Berry Consultants LLC, United States

Statistical Scientist

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.